E-LIB Suche - Ergebnisse für: Javier Loscertales

1

Evaluation of the novel therapeutic anti‐CCR7 antibody CAP‐..:

Mateu‐Albero, Tamara ; Marcos‐Jimenez, Ana ; Delgado‐Wicke, Pablo...
Hematological Oncology. 41 (2023) 5 - p. 869-876 , 2023

Link: https://doi.org/10.1002/..

2

Real-World Evidence on the Clinical Characteristics and Man..:

Loscertales, Javier ; Abrisqueta-Costa, Pau ; Gutierrez, Antonio...
Cancers. 15 (2023) 16 - p. 4047 , 2023

Link: https://doi.org/10.3390/..

3

Ibrutinib Does Not Impact CCR7-Mediated Homeostatic Migrati..:

Mateu-Albero, Tamara ; Marcos-Jimenez, Ana ; Wissmann, Stefanie...
Cancers. 14 (2022) 11 - p. 2729 , 2022

Link: https://doi.org/10.3390/..

4

Targeting cancer homing into the lymph node with a novel an..:

Cuesta-Mateos, Carlos ; Juárez-Sánchez, Raquel ; Mateu-Albero, Tamara...
mAbs. 13 (2021) 1 - p. , 2021

Link: https://doi.org/10.1080/..

5

Effect of ibrutinib on CCR7 expression and functionality in..:

Mateu-Albero, Tamara ; Juárez-Sánchez, Raquel ; Loscertales, Javier...
Cancer Immunology, Immunotherapy. 71 (2021) 3 - p. 627-636 , 2021

Link: https://doi.org/10.1007/..

6

Real-World Characteristics and Outcome of Patients Treated ..:

Abrisqueta, Pau ; Loscertales, Javier ; Terol, Maria José...
Clinical Lymphoma Myeloma and Leukemia. 21 (2021) 12 - p. e985-e999 , 2021

Link: https://doi.org/10.1016/..

7

Clinical outcome and prognostic factors of patients with Ri..:

Abrisqueta, Pau ; Delgado, Julio ; Alcoceba, Miguel...
British Journal of Haematology. 190 (2020) 6 - p. 854-863 , 2020

Link: https://doi.org/10.1111/..

8

Angioimmunoblastic T‐cell lymphoma after acute myeloid leuk..:

Iturrate, Isabel ; Loscertales, Javier ; Fernández‐Ruiz, Elena...
Clinical Case Reports. 8 (2020) 12 - p. 3493-3496 , 2020

Link: https://doi.org/10.1002/..

9

CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC..:

Cuesta-Mateos, Carlos ; Fuentes, Patricia ; Schrader, Alexandra...
Biomarker Research. 8 (2020) 1 - p. , 2020

Link: https://doi.org/10.1186/..

10

Final 5-year findings from the phase 3 HELIOS study of ibru..:

Fraser, Graeme A.M. ; Chanan-Khan, Asher ; Demirkan, Fatih...
Leukemia & Lymphoma. 61 (2020) 13 - p. 3188-3197 , 2020

Link: https://doi.org/10.1080/..

11

Systemic Exposure of Rituximab Increased by Ibrutinib: Phar..:

Lavezzi, Silvia Maria ; de Jong, Jan ; Neyens, Martine...
Pharmaceutical Research. 36 (2019) 7 - p. , 2019

Link: https://doi.org/10.1007/..

12

Economic evaluation of obinutuzumab in combination with chl..:

Rubio-Terrés, Carlos ; Casado, Luis Felipe ; Burgos, Amparo...
ClinicoEconomics and Outcomes Research. 8 (2016) - p. 475-484 , 2016

Link: https://doi.org/10.2147/..

13

Randomized phase 2 study of otlertuzumab and bendamustineve..:

Robak, Tadeusz ; Hellmann, Andrzej ; Kloczko, Janusz...
British Journal of Haematology. 176 (2016) 4 - p. 618-628 , 2016

Link: https://doi.org/10.1111/..

14

Recommendations on the clinical use of bendamustine in lymp..:

Peñalver, Francisco Javier ; Delgado, Julio ; Loscertales, Javier...
European Journal of Haematology. 96 (2015) 5 - p. 532-540 , 2015

Link: https://doi.org/10.1111/..

15

Preclinical activity of anti-CCR7 immunotherapy in patients..:

Cuesta-Mateos, Carlos ; Loscertales, Javier ; Kreutzman, Anna...
Cancer Immunology, Immunotherapy. 64 (2015) 6 - p. 665-676 , 2015

Link: https://doi.org/10.1007/..